

John D Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7169936/publications.pdf>

Version: 2024-02-01

51
papers

2,411
citations

304701

22
h-index

223791

46
g-index

59
all docs

59
docs citations

59
times ranked

4051
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucose metabolism in amyotrophic lateral sclerosis: it is bitter-sweet. <i>Neural Regeneration Research</i> , 2022, 17, 1975.	3.0	8
2	In Vivo Pharmacodynamic Method to Assess Complement C5a Receptor Antagonist Efficacy. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 41-51.	4.9	5
3	Unexpected Off-Target Activities for Recombinant C5a in Human Macrophages. <i>Journal of Immunology</i> , 2022, 208, 133-142.	0.8	1
4	A validated quantitative method for the assessment of neuroprotective barrier impairment in neurodegenerative disease models. <i>Journal of Neurochemistry</i> , 2021, 158, 807-817.	3.9	12
5	TDP-43 Puts the STING in ALS. <i>Trends in Neurosciences</i> , 2021, 44, 81-82.	8.6	14
6	Clinical and electrophysiological examination of pinch strength in patients with amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2021, 63, 108-113.	2.2	2
7	Complement: a global immunometabolic regulator in amyotrophic lateral sclerosis. <i>Neural Regeneration Research</i> , 2021, 16, 1210.	3.0	5
8	Chemical synthesis and characterisation of the complement C5 inhibitory peptide zilucoplan. <i>Amino Acids</i> , 2021, 53, 143-147.	2.7	12
9	Glucose clearance and uptake is increased in the SOD1 ^{G93A} mouse model of amyotrophic lateral sclerosis through an insulin-independent mechanism. <i>FASEB Journal</i> , 2021, 35, e21707.	0.5	9
10	Complement peptide receptors in GtoPdb v.2021.3. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2021, 2021, .	0.2	1
11	Intrinsic bias at non-canonical, β -arrestin-coupled seven transmembrane receptors. <i>Molecular Cell</i> , 2021, 81, 4605-4621.e11.	9.7	69
12	THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2021, 178, S27-S156.	5.4	337
13	The emerging role of complement in neuromuscular disorders. <i>Seminars in Immunopathology</i> , 2021, 43, 817-828.	6.1	9
14	Development of Potent and Selective Agonists for Complement C5a Receptor 1 with In Vivo Activity. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 16598-16608.	6.4	8
15	Development of Synthetic Human and Mouse C5a: Application to Binding and Functional Assays <i>In Vitro</i> and <i>In Vivo</i> . <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1808-1817.	4.9	4
16	The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins. <i>Glia</i> , 2020, 68, 407-421.	4.9	133
17	Is the C3a receptor antagonist SB290157 a useful pharmacological tool?. <i>British Journal of Pharmacology</i> , 2020, 177, 5677-5678.	5.4	3
18	Absence of the C5a Receptor C5aR2 Worsens Ischemic Tissue Injury by Increasing C5aR1-Mediated Neutrophil Infiltration. <i>Journal of Immunology</i> , 2020, 205, 2834-2839.	0.8	17

#	ARTICLE	IF	CITATIONS
19	Pharmacological characterisation of small molecule C5aR1 inhibitors in human cells reveals biased activities for signalling and function. <i>Biochemical Pharmacology</i> , 2020, 180, 114156.	4.4	47
20	Absence of Receptor for Advanced Glycation End Product (RAGE) Reduces Inflammation and Extends Survival in the hSOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. <i>Molecular Neurobiology</i> , 2020, 57, 4143-4155.	4.0	21
21	The Peripheral Immune System and Amyotrophic Lateral Sclerosis. <i>Frontiers in Neurology</i> , 2020, 11, 279.	2.4	57
22	Preclinical Pharmacokinetics of Complement C5a Receptor Antagonists PMX53 and PMX205 in Mice. <i>ACS Omega</i> , 2020, 5, 2345-2354.	3.5	64
23	The potential interplay between energy metabolism and innate complement activation in amyotrophic lateral sclerosis. <i>FASEB Journal</i> , 2020, 34, 7225-7233.	0.5	8
24	The ϵ C3aR Antagonist SB290157 is a Partial C5aR2 Agonist. <i>Frontiers in Pharmacology</i> , 2020, 11, 591398.	3.5	11
25	Complement peptide receptors (version 2020.5) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2020, 2020, .	0.2	0
26	C5a receptors C5aR1 and C5aR2 mediate opposing pathologies in a mouse model of melanoma. <i>FASEB Journal</i> , 2019, 33, 11060-11071.	0.5	23
27	THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: G protein-coupled receptors. <i>British Journal of Pharmacology</i> , 2019, 176, S21-S141.	5.4	519
28	The Complement Receptor C5aR2: A Powerful Modulator of Innate and Adaptive Immunity. <i>Journal of Immunology</i> , 2019, 202, 3339-3348.	0.8	97
29	Gut microbiota in ALS: possible role in pathogenesis?. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 785-805.	2.8	30
30	Revisiting the role of the innate immune complement system in ALS. <i>Neurobiology of Disease</i> , 2019, 127, 223-232.	4.4	35
31	Therapeutic blockade of HMGB1 reduces early motor deficits, but not survival in the SOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2019, 16, 45.	7.2	21
32	Complement dysregulation in the central nervous system during development and disease. <i>Seminars in Immunology</i> , 2019, 45, 101340.	5.6	85
33	Complement peptide receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. <i>IUPHAR/BPS Guide To Pharmacology CITE</i> , 2019, 2019, .	0.2	0
34	Defects in synaptic transmission at the neuromuscular junction precede motor deficits in a TDP ⁴³ Q331K transgenic mouse model of amyotrophic lateral sclerosis. <i>FASEB Journal</i> , 2018, 32, 2676-2689.	0.5	52
35	Development and validation of a LC-MS/MS assay for pharmacokinetic studies of complement C5a receptor antagonists PMX53 and PMX205 in mice. <i>Scientific Reports</i> , 2018, 8, 8101.	3.3	21
36	Complement C3a receptor modulates embryonic neural progenitor cell proliferation and cognitive performance. <i>Molecular Immunology</i> , 2018, 101, 176-181.	2.2	30

#	ARTICLE	IF	CITATIONS
37	Complement components are upregulated and correlate with disease progression in the TDP-43Q331K mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2018, 15, 171.	7.2	45
38	Pharmacological inhibition of complement C5a-C5aR1 receptor signalling ameliorates disease pathology in the hSOD1 ^{G93A} mouse model of amyotrophic lateral sclerosis. <i>British Journal of Pharmacology</i> , 2017, 174, 689-699.	5.4	79
39	Complement C5aR1 Signaling Promotes Polarization and Proliferation of Embryonic Neural Progenitor Cells through PKC η . <i>Journal of Neuroscience</i> , 2017, 37, 5395-5407.	3.6	63
40	Complement C5a-C5aR1 signalling drives skeletal muscle macrophage recruitment in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Skeletal Muscle</i> , 2017, 7, 10.	4.2	45
41	Noninvasive assessment of altered activity following restraint in mice using an automated physiological monitoring system. <i>Stress</i> , 2017, 20, 76-84.	1.8	6
42	Motor neuron disease proteins activate complement and generate C5a. <i>Molecular Immunology</i> , 2017, 89, 168.	2.2	0
43	Cortical synaptic and dendritic spine abnormalities in a presymptomatic TDP-43 model of amyotrophic lateral sclerosis. <i>Scientific Reports</i> , 2016, 6, 37968.	3.3	85
44	Therapeutic targeting of complement to modify disease course and improve outcomes in neurological conditions. <i>Seminars in Immunology</i> , 2016, 28, 292-308.	5.6	66
45	A pathogenic role for the C5a receptor, C5aR2, in mouse models of Huntington's and Parkinson's disease. <i>Immunobiology</i> , 2016, 221, 1209.	1.9	2
46	Absence of toll-like receptor 4 (TLR4) extends survival in the hSOD1G93A mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2015, 12, 90.	7.2	69
47	Role for terminal complement activation in amyotrophic lateral sclerosis disease progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E3-4.	7.1	45
48	Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. <i>Journal of Neuroinflammation</i> , 2013, 10, 119.	7.2	76
49	Silencing of ghrelin receptor expression inhibits endometrial cancer cell growth in vitro and in vivo. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013, 305, E305-E313.	3.5	14
50	Impairments to the GH-IGF-I Axis in hSOD1G93A Mice Give Insight into Possible Mechanisms of GH Dysregulation in Patients with Amyotrophic Lateral Sclerosis. <i>Endocrinology</i> , 2012, 153, 3735-3746.	2.8	21
51	The C5a anaphylatoxin receptor CD88 is expressed in presynaptic terminals of hippocampal mossy fibres. <i>Journal of Neuroinflammation</i> , 2009, 6, 34.	7.2	17